Amgen

1Q Revenues: $4.0 billion (+9%)

1Q Earnings: $1.2 billion (+5%)

Comments: U.S. and International product sales were up 8% to $3.0 billion and $904 million, respectively. Xgeva sales were $153 million, up 14%. Prolia sales were $88 million up 9%. Combined Neulasta and Neupogen sales increased 9% to $1.3 billion. Enbrel sales increased 7% to $938 million. Aranesp sales were down 11% to $518 million, primarily due to a decline in unit demand, while Epogen sales dropped 17% to $446 million, reflecting the impact of label and reimbursement changes.